Essay on ITP

Reading File

Finding Sources

Searching PubMed

"immune thrombocytopenia" AND treatment

Reading File

I now have comprehensive information to write a thorough essay on ITP. Let me compile it:

Immune Thrombocytopenic Purpura (ITP)

Definition and Classification

Immune thrombocytopenic purpura (ITP) — also called immune thrombocytopenia — is an autoimmune disorder characterized by isolated thrombocytopenia (platelet count < 100,000/mm³) resulting from autoantibody-mediated destruction of platelets and impaired platelet production. It is fundamentally a diagnosis of exclusion: secondary causes of thrombocytopenia must first be ruled out.

ITP is broadly classified into two clinical subtypes:

Acute ITP: Seen predominantly in children, often following a viral infection. It is self-limited and usually resolves spontaneously within weeks to months.
Chronic ITP: The predominant form in adults; it is a recurrent or persistent disorder lasting more than 12 months. This is the clinically more challenging form and the focus of most therapeutic effort.

Secondary ITP can occur in the setting of systemic lupus erythematosus, low-grade lymphoproliferative disorders (e.g., chronic lymphocytic leukemia), and HIV infection. — Goldman-Cecil Medicine

Epidemiology

ITP was classically described as a disease of young women, and this holds for many patients — with a modest female predominance in the 20–30-year age group. However, it is now clearly recognized that ITP occurs at any age and in either sex. There is a second peak of incidence after age 60, with equal sex distribution in older patients. — Goldman-Cecil Medicine, Mulholland & Greenfield's Surgery

Pathogenesis

The central mechanism of ITP involves autoantibodies (primarily IgG) directed against platelet surface glycoproteins, most commonly the GPIIb/IIIa or GPIb/IX complexes. These autoantibodies are detectable in approximately 80% of chronic ITP cases. — Robbins & Kumar Basic Pathology

The IgG-coated platelets are recognized by Fc receptors on macrophages, with the spleen serving as the primary site of both antibody production and platelet destruction. The spleen's critical role is confirmed by the clinical benefit of splenectomy, which produces complete remission in more than two-thirds of patients. — Robbins & Kumar Basic Pathology

However, the pathogenesis is not fully explained by antibody-mediated destruction alone:

Up to 50% of ITP patients lack demonstrable antiplatelet antibodies. — Mulholland & Greenfield's Surgery
T-cell-mediated mechanisms, including CD8⁺ cytotoxic T cells that directly destroy platelets, contribute in a subset of patients.
Impaired thrombopoiesis: TPO receptor agonist therapy works precisely because platelet production is also reduced — megakaryocyte maturation is suppressed by the same immune mechanisms.

The bone marrow response is compensatory: normal or increased megakaryocytes are characteristic, though platelet release is inadequate relative to peripheral destruction.

Clinical Features

Because ITP is a platelet disorder rather than a coagulation factor deficiency, the bleeding pattern is mucocutaneous rather than deep-tissue:

Petechiae (pinpoint, non-blanching hemorrhages in skin)
Ecchymoses (easy bruising)
Epistaxis and gingival bleeding
Menorrhagia in women
Hematuria, melena, or hematochezia in more severe cases
Conjunctival or retinal hemorrhage — a sign of impending intracranial bleed
Intracerebral or subarachnoid hemorrhage — uncommon but life-threatening

Fortunately, fewer than 5% of patients present with life-threatening hemorrhage. Fatigue and easy bruising are the most common presentations. Importantly, splenomegaly is absent in uncomplicated primary ITP; its presence suggests an underlying secondary cause. — Goldman-Cecil Medicine, Mulholland & Greenfield's Surgery

Diagnosis

ITP is a clinical diagnosis of exclusion. There is no single confirmatory test.

Key diagnostic steps:

Complete Blood Count (CBC): Isolated thrombocytopenia with otherwise normal counts. Platelet counts can range from mildly reduced to near zero (<5,000/μL in severe cases).
Peripheral Blood Smear: Decreased platelets, some of which may be larger than normal (reflecting young, newly released platelets). No schistocytes (which would suggest TTP/HUS).
Bone Marrow Examination: Not routinely required unless the CBC shows abnormalities beyond thrombocytopenia. When performed, it shows normal to increased megakaryocytes with otherwise normal marrow — a pattern shared with all destructive thrombocytopenias.
Antiplatelet Antibody Assays: Neither sensitive nor specific — not recommended as a routine diagnostic test. — Goldman-Cecil Medicine
Exclusion of secondary causes: Testing for HIV, hepatitis C, H. pylori, autoimmune disease (ANA, anti-dsDNA for SLE), and review of medications.

Differential diagnosis includes drug-induced thrombocytopenia, TTP/HUS, DIC, hypersplenism, bone marrow failure syndromes, and cyclic thrombocytopenia (a rare condition where counts spontaneously rebound with relatively mild bleeding).

Treatment

The treatment of ITP does not always need to be initiated at diagnosis. Asymptomatic patients with platelet counts >30,000/μL appear not to have significantly increased mortality from thrombocytopenia and can be observed without treatment. — Harrison's Principles of Internal Medicine 22E

Treatment is guided by platelet count + bleeding symptoms, with a step-wise approach:

First-Line Therapy

Corticosteroids remain the cornerstone of initial management:

Prednisone 1 mg/kg/day orally: Approximately 80% of patients respond; however, relapse is typical upon taper. Side effects (glucose intolerance, immunosuppression, osteoporosis, cataracts) increase with dose and duration.
High-dose dexamethasone 40 mg/day × 4 days (every 28 days for several cycles): May achieve higher initial response rates and is generally better tolerated than prolonged prednisone; some trials show no difference in long-term outcomes.

IVIgG (Intravenous Immunoglobulin):

Dose: 1 g/kg/day × 2 days, or 0.4 g/kg/day × 5 days
Response rate ~80%; effects typically last 2–4 weeks
Works by blocking Fc receptors on splenic macrophages (and likely via other mechanisms)
More efficacious than anti-Rh(D) in post-splenectomized patients
Preferred when a rapid rise in platelet count is needed (e.g., pre-operatively or in bleeding emergency)

Anti-Rh(D) Immunoglobulin (Rho[D] immune globulin, 50–75 μg/kg IV):

Works through limited hemolysis of Rh(D)-coated RBCs, saturating Fc receptors and reducing platelet destruction
Only effective in Rh(D)-positive, non-splenectomized patients
FDA advises 8-hour monitoring post-infusion due to rare severe intravascular hemolysis

For patients with severe ITP (platelet < 5,000/μL) or active hemorrhage, hospital admission is required with combined-modality therapy: high-dose glucocorticoids + IVIgG ± additional immunosuppressants. Platelet transfusions may be given but are only briefly effective due to ongoing destruction.

Second-Line Therapy

Rituximab (anti-CD20 monoclonal antibody):

Depletes B cells and reduces autoantibody production
Effective in refractory ITP; however, durable long-term remission occurs in only ~30% of patients
Not currently FDA-approved specifically for ITP, though widely used

Thrombopoietin Receptor Agonists (TPO-RAs):

Stimulate megakaryocyte production to overcome the platelet deficit
Romiplostim (subcutaneous injection)
Eltrombopag (oral)
Avatrombopag (oral)
70–95% of patients see platelet count improvement; sustained response in 40–60%
Now preferred over broad immunosuppression or splenectomy for chronic ITP due to more favorable side-effect profiles and quality-of-life outcomes — Harrison's Principles of Internal Medicine 22E
Recent network meta-analyses (2025) confirm efficacy across pediatric and adult populations [PMID: 40547032, 40196346]

Fostamatinib (oral SYK inhibitor):

A newer agent for refractory ITP; meta-analysis confirms efficacy in randomized trials [PMID: 38856778]

Emerging options: Mycophenolate mofetil is emerging as a possible first-line agent under expert supervision. — Goldman-Cecil Medicine

Splenectomy

Splenectomy removes the primary site of both antibody production and platelet destruction:

Complete remission in >65–70% of patients; however, up to 30% relapse over time
Now reserved for patients who have required treatment for >12 months and failed other options, or who cannot tolerate medical therapy
Pre-operative vaccination against encapsulated organisms (pneumococcus, meningococcus, H. influenzae) is mandatory to reduce risk of overwhelming post-splenectomy sepsis
Laparoscopic approach is standard when feasible
Accessory spleens are a rare cause of relapse post-operatively

The use of splenectomy for ITP has declined significantly as TPO-RAs and rituximab have become available, given the risks of post-splenectomy infections. — Mulholland & Greenfield's Surgery

Special Populations

Children: Acute ITP following viral infection is typically self-limited. Observation is appropriate for most cases; major bleeding is rare.

Pregnancy: Maternal ITP requires careful management because maternal antiplatelet IgG can cross the placenta and cause neonatal thrombocytopenia. Management involves a balance between controlling maternal platelet counts and minimizing fetal/neonatal risk.

Secondary ITP: Treating the underlying condition (e.g., antiretrovirals for HIV, rituximab + chemotherapy for CLL) is integral to management.

Prognosis

The natural history varies widely. Pediatric acute ITP generally resolves without specific treatment. Adult chronic ITP is often a lifelong relapsing-remitting condition, though spontaneous sustained remissions do occur — and notably, many patients who achieve complete response to a TPO-RA will maintain a sustained response even after discontinuing therapy. — Harrison's Principles of Internal Medicine 22E

Mortality directly attributable to ITP is uncommon; the most feared complication is intracranial hemorrhage, occurring in <1% of patients, predominantly at very low platelet counts (<10,000/μL) with additional risk factors.

Summary

ITP is an autoimmune thrombocytopenia driven by antiplatelet IgG antibodies (primarily against GPIIb/IIIa and GPIb/IX), with the spleen as the central organ of platelet destruction and antibody production. The clinical picture is dominated by mucocutaneous bleeding; the diagnosis is clinical and by exclusion. Management has evolved substantially — from reliance on steroids and splenectomy toward a patient-centered, stepwise approach incorporating TPO receptor agonists and rituximab, with splenectomy now reserved for refractory cases. Not every patient requires immediate treatment; the threshold for intervention is guided by platelet count, bleeding symptoms, and patient-specific risk factors.

Sources:

Harrison's Principles of Internal Medicine, 22nd ed. (2025)
Goldman-Cecil Medicine, International Edition
Robbins & Kumar Basic Pathology (Robbins Pathology)
Robbins, Cotran & Kumar Pathologic Basis of Disease
Mulholland & Greenfield's Surgery, 7th ed.
Recent evidence: TPO-RA meta-analyses [PMID: 40547032, 40196346]; Fostamatinib [PMID: 38856778]

This is a shared conversation. Sign in to Orris to start your own chat.